Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

Core Insights - Organovo Holdings, Inc. has appointed Norman Staskey as Chief Financial Officer, bringing over 25 years of experience in capital markets and M&A transactions, particularly in the biotech sector [1][2][3] Company Developments - The company’s lead drug, FXR314, has shown promising results in treating liver fibrosis and inflammatory bowel disease (IBD), with significant reductions in liver fat content and improved epithelial barrier function in clinical studies [3][4][5] - FXR314 is expected to enter a Phase 2 study for moderate to severe ulcerative colitis, with potential for both monotherapy and combination therapy applications [5][6] Research and Clinical Trials - In 2024, Organovo demonstrated FXR314's effectiveness in 3D human cellular models for Crohn’s disease and ulcerative colitis, showing strong performance in improving key disease measures [4][5] - The Phase 2 study results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) were presented at a major conference, highlighting its safety profile and efficacy [3][4]